Comparative Utility of Aripiprazole and Haloperidol in Schizophrenia

被引:0
|
作者
Kane, John [1 ]
Kim, Edward [2 ]
Kan, Hong [3 ]
Guo, Zhenchao [3 ]
Bates, John [2 ]
Whitehead, Richard [4 ]
Pikalov, Andrei [4 ]
机构
[1] Zucker Hillside Hosp, Glen Oaks, NY USA
[2] Bristol Myers Squibb, Plainsboro, NJ USA
[3] Bristol Myers Squibb, Wallingford, CT USA
[4] Otsuka Amer Pharmaceut Inc, Rockville, MD USA
关键词
D O I
10.1007/BF03256145
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: Since their introduction, second-generation antipsychotics (SGAs) have become the drugs of choice for the treatment of schizophrenia. However, recent findings have questioned the benefits of SGAs over first-generation antipsychotics (FGAs). Objective: This post hoc analysis sought to compare the utility of the SGA aripiprazole with the FGA haloperidol in patients with early-phase schizophrenia (ES) or chronic schizophrenia (CS). Method: Data were pooled from two identical 52-week, randomized, active comparator trials (31-98-217 and 31-98-304) of aripiprazole 20-30 mg/day versus haloperidol 7-10 mg/day. Patients in the efficacy sample were classified as having ES if they were <= 40 years of age with a duration of illness <= 5 years. All other patients were classified as having CS. Health-state utilities were derived from the Positive and Negative Syndrome Scale and adverse events, using the last observation carried forward method. Results: Of 1294 patients in the efficacy sample, 362 met criteria for ES (aripiprazole, n = 239; haloperidol, n = 123) and 932 met criteria for CS (aripiprazole, n = 622; haloperidol, n = 310). Baseline patient characteristics were similar between treatment arms. At week 52, patients treated with aripiprazole in the total and ES populations had significantly greater total utility than those treated with haloperidol, although there were no statistically significant differences in total utility for the CS population at week 52. For the total population, patients treated with aripiprazole had significantly higher quality-adjusted life days (QALDs)/year than haloperidol recipients (+6.48 QALDs/ year, p = 0.02). Significantly higher QALDs/year were also seen for aripiprazole-treated patients with ES (+10.65 QALDs/year, p = 0.04) but not for patients with CS (+4.92 QALDs/year, p = 0.14), compared with haloperidol-treated patients. Conclusions: Aripiprazole demonstrates greater utility than haloperidol over 52 weeks of treatment. This difference was driven by superiority of aripiprazole over haloperidol in patients with ES, which was not observed in patients with CS.
引用
收藏
页码:109 / 119
页数:11
相关论文
共 50 条
  • [21] Cost-utility analysis of aripiprazole and haloperidol in early-episode schizophrenia (studies 31-98-217 and 31-98-304)
    Pikalov, A.
    Kane, J. M.
    Kim, E.
    Kan, H. J.
    Guo, Z.
    Whitehead, R.
    Bates, J.
    Werner, C.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 135 - 135
  • [22] Aripiprazole for schizophrenia
    El-Sayeh, H. G.
    Morganti, C.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (02):
  • [23] A comparative study of short term efficacy of aripiprazole and risperidone in schizophrenia
    Pandey, Ravi S.
    Jagadisha, T.
    Kumar, Sajeev
    Sivakumar, P. T.
    Kumar, C. Naveen
    INDIAN JOURNAL OF PSYCHIATRY, 2013, 55 (05) : S117 - S117
  • [24] A randomized comparative study of perospirone and aripiprazole for Japanese schizophrenia patients
    Takekita, Y.
    Kato, M.
    Sakai, S.
    Suwa, A.
    Wakeno, M.
    Okugawa, G.
    Kinoshita, T.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 106 - 107
  • [25] Efficacy and safety of intramuscular aripiprazole, haloperidol or placebo in acutely agitated patients with schizophrenia or schizoaffective disorder
    Oren, D
    Marcus, R
    Kostic, D
    McQuade, R
    Iwamoto, T
    Archibald, D
    SCHIZOPHRENIA BULLETIN, 2005, 31 (02) : 499 - 499
  • [26] Aripiprazole for Patients with Schizophrenia and Schizoaffective Disorder: An Open-Label, Randomized, Study Versus Haloperidol
    de Oliveira, Irismar Reis
    Elkis, Helio
    Gattaz, Wagner Farid
    Chaves, Ana Cristina
    de Sena, Eduardo Ponde
    de Matos e Souza, Fabio Gomes
    Campos, Joao Alberto
    Bueno, Joao Romildo
    Costa e Silva, Jorge Alberto
    Louza, Mario Rodrigues
    de Abreu, Paulo Belmonte
    CNS SPECTRUMS, 2009, 14 (02) : 93 - 102
  • [27] Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia
    Docherty, J. P.
    Baker, R. A.
    Eudicone, J.
    Mathew, S.
    Marcus, R. N.
    McQuade, R. D.
    Mankoski, R.
    SCHIZOPHRENIA RESEARCH, 2010, 120 (1-3) : 199 - 203
  • [28] Incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia or schizoaffective disorder
    Miller, Delwyn D.
    Kim, Edward
    Eudicone, James
    Pikalov, Andrei A.
    Vester-Blokland, Estelle
    Coryell, William H.
    NEUROPSYCHOPHARMACOLOGY, 2006, 31 : S123 - S123
  • [29] Haloperidol, olanzapine and risperidone reduce treatment failure compared to aripiprazole, quetiapine and ziprasidone in acute schizophrenia
    Taylor, David
    EVIDENCE-BASED MENTAL HEALTH, 2007, 10 (03) : 76 - 76
  • [30] Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia
    Sharma, Sanya
    Sidana, Ajeet
    Mehta, Shivangi
    Bajaj, Manoj Kumar
    INDIAN JOURNAL OF PSYCHIATRY, 2023, 65 (10) : 1044 - 1051